Teijin Limited

Yataro Ichikawa

Teizo Yamaji

Koji Nakagawa

Toshiyuki Hiramatsu

Shizuo Azuma

Yoshihiko Sumi

Hideki Tsuruta

Yoshiyuki Yamanaka

Nobuo Aoki

Eishin Yoshisato

Mamoru Yamamoto

Satoshi Nakamura

Takeshi Watanabe

Yukiya Koike

Kazuo Kitai

Tsukio Masegi

Akira Kudo

Arata Kato

Jun Suzuki

Nobuo Suzuki

Toru Sawaki

Yoji Suzuki

Masami Muramatsu

Michiyuki Tokashiki

Tsuto Morinaga

Kimihiko Hamamoto

Kunitada Shimotohno

Yuitsu Honda

Tatuyuki Naruchi

Kin-ichiro Miura

Yushi Nishimura

Kenji Wakabayashi

Kazuhiko Soma

Osamu Kobayashi

Noriyuki Tsunekawa

Kenichi Kato

Kenji Yone

Masami Fukuoka

Masato Ikegami

Takashi Sugiyama

Yoshinori Kato

Sachio Ishimoto

Hisao Yamaguchi

Toshiaki Harada

Koji Suzuki

Kenji Ishimaru

Takeo Oba

Takami Arai

Hiroshi Imai

Syoji Ono

Yoichi Sakata

Nobuhiko Yoshida

Jun Mimuro

Koichiro Sakota

Kenji Ozawa

Hitoshi Ohmori

Akiko Azuma

Yoshiko Kawakami

Masami Murakami

A protein having human plasmin inhibiting activity, substantially equivalent reactivity with human plasmin to a human .alpha..sub.2 -plasmin inhibitor derived from plasma, a binding ability to human fibrin about 1/4 to about 1/3 of that of the human .alpha..sub.2 -plasmin inhibitor derived from plasma, and a molecular weight of about 50,000 to about 77,000.

Protein having human plasmin inhibiting activity

This invention provides a monoclonal antibody or its fragment specific to a human .alpha..sub.2 -plasmin inhibitor, said antibody having the function of specifically blocking that site of the human .alpha..sub.2 -plasmin inhibitor which inhibits the fibrinolytic activity of plasmin, and of suppressing said fibrinolytic activity inhibiting function of said .alpha..sub.2 -plasmin inhibitor, and also a hybridoma capable of producing the monoclonal antibody. Said monoclonal antibody or its fragment is useful for the immunological determination of a human .alpha..sub.2 -plasmin inhibitor, the separation or recovery of a human .alpha..sub.2 -plasmin inhibitor from a liquid containing the human .alpha..sub.2 -plasmin inhibitor, and the treatment of a thrombotic disease.

Monoclonal antibody specific to human .alpha..sub.2 -plasmin inhibitor

In methods for immunologically assaying free lipoprotein associated coagulation inhibitor (hereafter abbreviated as 'LACI') in a human inspection sample using a first antibody immobilized on an insoluble carrier and a labeled second antibody, a method for immunological assay of free LACI and a kit therefor wherein

Method for immunological assay of free lipoprotein associated

Terminal modifications of tumor necrosis factor

cDNA encoding a human .alpha..sub.2 -plasmin inhibitor precursor protein represented by an amino acid sequence from the -39th Met to the 452nd Lys in FIG. 1 of the accompanying drawings; an amino acid sequence of a human .alpha..sub.2 -plasmin inhibitor precursor represented by an amino acid sequence from the -39th Met to the 452nd Lys in FIG. 1 of the accompanying drawings; and genomic DNA encoding a human .alpha..sub.2 -plasmin inhibitor protein which is composed of exons II, III, IV, V, VI, VII, VIII, IX and X in FIG. 4 of the accompanying drawings, said exons being bonded to one another via introns.

cDNA and genomic DNA encoding the amino acid sequence of human

A method of immunologically determining free human protein S in an assay sample, which comprises contacting a primary antibody fixed to an insoluble solid carrier and a labelled secondary antibody with the assay sample, the primary and secondary antibodies having the property of binding to different epitopes of free human protein S, and one of the primary and secondary antibodies being a monoclonal antibody having the property of not binding to a complex of the human protein S and human complement cofactor C4b-binding protein (C4bp) but specifically binding to the free human protein S. Also provided is a method of immunologically determining a complex of human protein S and human complement cofactor C4b-binding protein (C4bp) in an assay sample, which comprises contacting a primary antibody fixed to an insoluble solid carrier and a labelled secondary antibody with the assay sample, one of the primary and secondary antibodies being a monoclonal antibody having the property of not binding to free human protein S and human complement cofactor C4b-binding protein (C4bp) but binding specifically to the complex, and the other being an antibody having the property of binding to the human complement cofactor C4b-binding protein (4Cbp).

Immunological determination of free human protein S and C4bp-protein S

A method of cultivating animal or plant cells, which consists essentially of contacting a cultivation liquor having animal or plant cells suspended therein with a liquid fluorocarbon having molecular oxygen dissolved therein, characterized in that said cultivation liquor forms a continuous suspension phase which has cell densities of at least 4.times.10.sup.6 cells/ml, that said contact is made by feeding said liquid fluorocarbon into the cultivation liquor from above the cultivation liquor such that 1 ml of liquid fluorocarbon has a surface area of about 6 to about 300 cm.sup.2 whereby the liquid fluorocarbon falls downward through the cultivation liquor by gravity, and that said cultivation liquor has a volume of at least about 10 liters.

Method of cultivating animal or plant cells

The present invention provides an enhancer DNA segment, a gene fragment having (a) the enhancer DNA segment and (b) a structural gene such as human D, V and J gene, and a promoter. A hybrid DNA (1) having a phage DNA fragment from Charon 4A phage vector and human DNA fragments, a Charon 4A phage containing the hybrid DNA (1), a hybrid DNA (2) having a PBR322 fragment and human DNA fragment, a transformant of E. coli C600 strain transformed with the hybrid DNA (2), plasmid pSV2-H1G1 obtained by inserting a human DNA fragment into a vector pSV-2gpt, a transformant of E. coli MC 1000 strain transformed with the plasmid pSV2-H1G1 and a transformant of mouse myeloma cells J558L or NS-1 transformed with the plasmid pSV2-H1G1 are also provided.

Human immunoglobulin and enhancer gene fragments

A method of confirming the diagnosis of Kawasaki disease in a patient which comprises assaying the patient's body fluid for the presence of elevated levels of a substance specifically bound by an anti-tumor necrosis factor monoclonal antibody.

Method of detecting Kawasaki disease using anti-tumor necrosis antibody

A novel physiologically active polypeptide having antitumor activity obtained by improving human tumor necrosis factor (TNF). The amino acid sequence of the polypeptide essentially corresponds to that of human tumor necrosis factor, except that ten amino acids Nos. 1 to 10 are deleted and (Met).sub.n -Arg-Lys-Arg are added to the amino (NH.sub.2)-terminus, where n is 0 or 1. Other amino acid modifications can also be made to the polypeptide while retaining high antitumor activity. The novel polypeptide has less side effects that the natural-type TNF, particularly with respect to cytotoxicity. A a DNA fragment encoding the polypeptide, a recombinant plasmid containing the DNA fragment, a recombinant microorganism cell transformed with the plasmid, a method of producing a novel physiologically active polypeptide using the microorganism cell, and a pharmaceutical composition comprising the polypeptide as an active ingredient are also provided.

Muteins of tumor necrosis factor

A mouse-human chimaeric immunoglobulin heavy chain comprising (a) the amino acid sequence of a mouse immunoglobulin heavy chain variable region and (b) the amino acid sequence of a human immunoglobulin heavy chain constant region and reacting specifically with human common acute lympohocytic leukemia antigen and a chimaeric DNA fragment which encodes the amino acid sequence of the above mouse-human chimaeric immunoglobulin heavy chain.

Mouse-human chimaeric immunoglobulin heavy chain specific for the call

A monoclonal antibody which is specific to human protein C which has calcium bound at the gammacarboxyglutamic acid(Gla) domain and does not recognize human protein C which is not bound to calcium at the Gla domain. The monoclonal antibody is used in an immunoassay method for determining human protein C having a Gla domain and in a method for recovering human protein C having a Gal domain.

Monoclonal antibody to human protein C

A plant metabolism regulating agent comprising as an active ingredient an alpha,beta or beta,gamma-un-saturated carboxylic acid or its derivative. It is useful for controlling the metabolism of a plant, facilitating the growth of a beneficial plant such as cereals by inhibiting the growth of undesirable plants or eradicating them, regulating the growth of a plant and dwarfing a plant.

Regulation of plant metabolism by alpha, beta-or beta, gamma-unsaturated

Double-stranded DNA characterized by having sequences complementary to a single-stranded DNA which has a molecular size of about 2.67 Kb and is derived from mungbean yellow mosaic virus, and giving the restriction endonuclease cleavage map shown in FIG. 1 of the accompanying drawings; and double-stranded DNA characterized by having sequences complementary to a single-stranded DNA which has a molecular size of about 2.70 Kb and is derived from mungbean yellow mosaic virus, and giving the restriction endonuclease cleavage map shown in FIG. 2 of the accompanying drawings; and hybrid DNAs having the double-stranded DNAs inserted thereinto.

Double-stranded DNA having sequences complementary to a single-stranded

Growing community of inventors

Tokorozawa, Japan

Yataro Ichikawa